TRCT
TPTX

Tower Research Capital (TRC)’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,941
Closed -$372K – 6925
2022
Q2 		$372K Buy
4,941
+3,774
+323% +$168K 0.01% 1323
2022
Q1 		$31K Sell
1,167
-5,317
-82% -$179K ﹤0.01% 3130
2021
Q4 		$309K Buy
6,484
+1,614
+33% +$72.2K 0.01% 1461
2021
Q3 		$324K Buy
4,870
+2,838
+140% +$202K 0.01% 1323
2021
Q2 		$158K Sell
2,032
-1,336
-40% -$98.7K ﹤0.01% 2097
2021
Q1 		$319K Buy
3,368
+686
+26% +$81.6K 0.01% 1625
2020
Q4 		$327K Buy
2,682
+1,586
+145% +$174K 0.01% 1326
2020
Q3 		$96K Sell
1,096
-4,041
-79% -$282K ﹤0.01% 3179
2020
Q2 		$332K Buy
+5,137
New +$296K 0.01% 1362
2020
Q1 		– Sell
-566
Closed -$35K – 4239
2019
Q4 		$35K Sell
566
-982
-63% -$46.7K ﹤0.01% 1569
2019
Q3 		$58K Buy
1,548
+942
+155% +$41K ﹤0.01% 1690
2019
Q2 		$25K Buy
+606
New +$21.6K ﹤0.01% 2036

Tower Research Capital (TRC)'s TPTX Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 4,941 shares — an estimated $372K sold.

Tower Research Capital (TRC) first reported a position in TPTX in Q2 2019 and held it in 12 quarters. The position peaked at $372K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Tower Research Capital (TRC) reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 4,941 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $372K.
  • Tower Research Capital (TRC) first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s Turning Point Therapeutics, Inc. Common Stock position peaked at $372K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.